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longitudinal marker of disease progression in
Huntington’s disease
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Background: Current clinical assessments of motor function in Huntington’s Disease (HD) rely on subjective ratings
such as the Unified Huntington’s Disease Rating scale (UHDRS). The ability to track disease progression using
simple, objective, inexpensive, and robust measures would be beneficial.
Methods: One objective measure of motor performance is hand-tapping. Over the last 14 years we have routinely
collected, using a simple device, the number of taps made by the right and left hand over 30 seconds in HD
patients attending our NHS clinics.
Results: Here we report on a longitudinal cohort of 237 patients, which includes patients at all stages of the
disease on a wide range of drug therapies. Hand tapping in these patients declines linearly at a rate of 5.1 taps per
year (p < 0.0001; 95% CI = 3.8 to 6.3 taps), and for each additional year of age patients could perform 0.9 fewer taps
(main effect of age: p = 0.0007; 95% CI = 0.4 to 1.4). Individual trajectories can vary widely around this average rate
of decline, and much of this variation could be attributed to CAG repeat length. Genotype information was
available for a subset of 151 patients, and for each additional repeat, patients could perform 5.6 fewer taps
(p < 0.0001; 95% CI = 3.3 to 8.0 taps), and progressed at a faster rate of 0.45 fewer taps per year (CAG by time
interaction: p = 0.008; 95% CI = 0.12 to 0.78 taps). In addition, for each unit decrease in Total Functional Capacity
(TFC) within individuals, the number of taps decreased by 6.3 (95% CI = 5.4 to 7.1, p < 0.0001).
Conclusions: Hand tapping is a simple, robust, and reliable marker of disease progression. As such, this simple motor
task could be a useful tool by which to assess disease progression as well therapies designed to slow it down.
Keywords: Huntington’s disease, Biomarker, Hand tappingBackground
Huntington’s disease (HD) is an autosomal dominant
neurodegenerative disorder that is caused by the expres-
sion of mutant huntingtin secondary to a polyglutamine
(CAG) expansion in exon 1 of the huntingtin gene [1].
The disease is characterised by the dysfunction, and then
loss, of specific neuronal populations especially in the
striatum as well as in the cerebellar cortex, thalamus,
cerebral cortex and hippocampus [2,3] in association with
early posterior white matter changes [3-5]. Typically
patients present in mid life with an array of motor* Correspondence: stan.lazic@cantab.net
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reproduction in any medium, provided the orsigns including chorea and bradykinesia as well as psy-
chiatric and cognitive impairments [6]. Many studies
have sought to identify the earliest changes in HD and
subtle impairments in motor and cognitive function before
predicted disease onset have been reported [7,8]. Others
have sought to more objectively track disease progression
once the disease has become manifest and this includes a
range of motor, cognitive and imaging approaches [4,9].
Such objective markers are increasingly needed as we move
towards a time when disease modifying therapies for HD
are coming to trial [10].
Currently the gold standard for looking at motor im-
pairments in HD is the Unified Huntington’s Disease
Rating Scale (UHDRS), which was primarily designed for
manifest HD [11]. The UHDRS however, is susceptibleLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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sensitivity in early HD patients [12]. We, and others, have
therefore sought to find simple motor measures which may
be accurately used for tracking disease. In the TRACK-HD
baseline analysis, voluntary self paced finger tapping
was shown to be a sensitive task in premanifest patients
and is associated with disease burden in HD patients [4].
Speed finger tapping tasks used in cross-sectional studies
has also been shown to be a sensitive early marker of
change in premanifest and manifest HD, with the defi-
cits being more pronounced in later stages of HD [13].
These late change deficits also correlate with atrophy on
MRI and clinical scores in HD patients thereby linking
structure to function [13]. In another cross-sectional
study HD patients had larger variability in hand and finger
tapping rates compared with controls and this correlated
with cognitive impairments in these patients [14]. In a
pre-diagnostic study changes in button tapping showed
a significant change in rate of decline as the subjects
neared disease onset [13]. In the Predict-HD study, pre-
manifest HD patients also showed variability in speed and
self paced tapping although this needs to be validated
with longitudinal follow up [15]. Collectively, the data
from the TRACK-HD study showed that tapping speed
was a robust measure in premanifest and HD patients at
12, 24, and 36 months [5,9,16]. Premanifest patients also
showed a decrease in the number of taps performed in
the Predict-HD study at 2 years follow up [17]. Our
group has previously shown in a 10 year follow up study
that the rate of decline in hand tapping correlated with
UHDRS motor scores [18].
In addition to hand and finger tapping, other motor
measures have been found to be sensitive markers of
disease progression including grip force and tongue
protrusion tasks. Similar to tapping, performance on these
tasks also deteriorates over time in both premanifest
patients close to disease onset and in manifest patients in
comparison to controls [5,9,17]. The oculomotor system
has also been studied in HD and correlates with other
motor features [19], even in longitudinal follow up [20].
In particular, changes in saccades such as increased error
rates, saccade latency and increased variability of saccade
latency has been shown in premanifest and HD patients,
with increasing abnormalities in advanced HD patients
[19]. Over a three year period premanifest and HD pa-
tients displayed significantly increased saccade latencies
compared to controls, which could be used as a predictor
of time to disease onset in premanifest patients [20].
Finally, attempts have been made to look at more com-
plex motor tasks such as the use of the peg board test,
which measures the time taken to insert 25 pegs from a
rack into a series of appropriate holes [21]. It has been
shown that patients are impaired in this task, although
there does not appear to be any significant difference inpatients in the premanifest versus manifest stages of the
illness [21,22]. When testing complex tasks, execution
speed of rapid alternating motion sequences are slower
in HD patients compared to controls [23].
In the analysis reported in this paper, we have used
a simple hand tapping task, which we have previously
shown to be useful in a small cohort of patients followed
over time [18]. We now report on the utility of this test in
a much larger numbers of patients followed over a longer
period of time (up to 14 years), to show that this single
measure gives a robust annual decline irrespective of dis-
ease stage and therefore could be used as one of an array
of assessment tools in trials in manifest HD.
Methods
Patients
237 patients were recruited from the regional NHS HD
clinic at the Cambridge Centre for Brain Repair between
1998 and 2012, and hand tapping data was collected as part
of their routine clinical assessment. Patients were seen typic-
ally at intervals of approximately 6 or 12 months, although
some were seen more frequently for reasons of clinical care
and management. All patients included in the analysis were
seen for at least one year and for at least three visits and all
were taking their normal medication for their HD. There
were no inclusion or exclusion criteria outside of this, and
thus and the patients are a representative sample of patients
with HD. This analysis was classified as a service evaluation
and registered with the Patient Safety Unit at Addenbrooke’s
Hospital (Project Register Number: 3026). Since hand tap-
ping data was not initially collected for research purposes
and the analysis used fully anonymised data, ethics review
was not required and informed consent was not obtained.
All patients had a positive genetic test for HD or had fea-
tures of the disease and came from a known HD family and
were diagnosed as having manifest disease when they had a
diagnostic confidence level score of >3. The calculated long
allele CAG length for the patients in our cohort ranged
from 37 to 62 repeats, this was calculated by PCR analysis
as previously described [24]. Many of the patients had their
genetic test before 2001 when the exact repeat number
was not routinely recorded. In those where a CAG length
was known (n = 151), their demographic information is
summarised in Table 1. The patients overall total functional
capacity (TFC) [25,26] was assessed using the UHDRS
which ranges from 0–13, with 13 equating to normal in-
dependent life and 0 to a total dependence on others.
The motor UHDRS score was calculated at the patients
first visit and ranged from 0–86. Higher scores indicate
a more severe motor impairment [11].
Hand tapping device
The original hand-tapping device was designed as a simple
objective measure of motor function for use in the routine
Table 1 Demographic information at first visit
All patients With CAG information
(Male = 115, Female = 122) (Male = 71, Female = 80)
Mean (SD) Range Mean (SD) Range
Age
Male 49.1 (13.7) 14.0 – 75.6 47.3 (13.5) 14.1 – 75.6
Female 50.0 (12.8) 18.5 – 77.9 49.3 (12.9) 18.8 – 77.9
Follow up (years)
Male 4.6 (2.6) 1.0 – 12.9 4.7 (2.3) 1.3 – 10.6
Female 4.9 (2.5) 1.0 – 14.1 4.5 (2.3) 1.0 – 14.1
Number of visits
Male 7.1 (4.9) 3 – 25 6.8 (4.2) 3 – 22
Female 6.6 (4.2) 3 – 26 6.6 (3.5) 3 – 26
TFC
Male 9.5 (3.4) 2 – 13 10.4 (2.9) 3 – 13
Female 9.1 (3.4) 3 – 13 9.5 (3.3) 3 – 13
UHDRS motor score
Male 23.3 (17.1) 0 – 86 20.2 (13.6) 0 – 51
Female 25.8 (18.4) 0 – 70 23.3 (17.5) 0 – 62
Disease duration (years)
Male 5.3 (3.3) 0.1 – 17.0 4.4 (2.4) 0.1 – 10.5
Female 5.4 (3.2) 0.2 – 15.8 4.7 (2.4) 0.4 – 14.2
CAG length
Male 44.6 (5.1) 39 – 62
Female 43.4 (3.9) 37 – 61
Information is provided separately for the complete data set (N = 237) and for patients with information on CAG repeat length (N = 151).
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6 cm in diameter, mounted with their centres 30 cm apart.
The subject is asked to alternately tap one button after the
other as rapidly as possible using their right hand for
30 seconds, and then again with their left hand. The total
number of taps for each hand is recorded manually and
then summed to give a total number of taps for both
hands. This device is different to that used previously by
us, which was a more sophisticated device that automat-
ically downloaded data onto a computer and calculated
inter tap intervals [18]. Hence, the device used in the
present study only allowed us to collect data on the total
number of taps.
Statistical analysis
The main outcome for all analyses was the total number
of taps, which was the sum of the number of taps made
with the left and right hand. Even though the data are
counts (non-negative integers), the data distribution was
approximated well by a normal model (the values were
far away from zero), which was therefore used instead of
a Poisson or negative binomial model. The first analysis
used all 237 patients and estimated the change in numberof taps over time with a mixed-effects model. Fixed factors
were time (since first visit), age at first visit, sex, and time
by sex interaction. The random factors were patient and
patient by time interaction (varying intercepts and varying
slopes). The serial dependence of observations within
patients was modeled using an exponential correlation
structure. The second analysis used the 151 patients for
which information on CAG length was available. The same
mixed-effects model as the first analysis was used with the
addition of CAG length as a continuous variable and the
removal of the non-significant time by sex interaction.
Finally, the relationship between tapping and TFC
was examined with a mixed-effects model using the
227 patients for which TFC data was available. The model
included a fixed effect of age, sex, and TFC, and random
effects for patient and patient by TFC interaction. Analysis
was conducted with R (3.0.0).
Results
Change in hand tapping over time for all patients
The number of taps declined linearly over time; patients
performed 5.1 fewer taps each year (main effect of time:
p < 0.0001; 95% CI = 3.8 to 6.3 taps; Figure 1) with no
Figure 1 Change in hand tapping over time by sex. Individual profiles for 237 patients (A) and the population averages with 95% CI
(dashed lines; B). On average, patients performed 5.1 fewer taps each year (p < 0.0001), but there were large differences in hand tapping scores
between patients. This can be seen in panel (C), which shows the estimated annual change for each individual. The population mean is indicated
with the triangle on the x-axis.
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sex interaction: p = 0.207; Figure 1B), although females on
average performed approximately 28 fewer total taps than
males (main effect of sex; p = 0.0001). The estimates foreach individual are shown in Figure 1C and it should be
noted that the individuals in the tails of the distribution
were not necessarily the ones with the fewest observations
or the shortest follow up time. Older patients performed
Collins et al. BMC Neurology 2014, 14:35 Page 5 of 8
http://www.biomedcentral.com/1471-2377/14/35fewer taps than younger patients; so for each additional
year of age, patients performed 0.9 fewer taps (main effect
of age: p = 0.0007; 95% CI = 0.4 to 1.4). Nevertheless, if we
assume that patients would have decreased at a rate of 0.9
taps per year in the absence of the disease, then approxi-
mately 82% of the annual decrease can be attributed to the
effect of the disease ([(5.1 - 0.9)/ 5.1] * 100 = 82%).
A greater number of CAG repeats is associated with a
faster rate of decline in hand tapping
In this cohort CAG repeat lengths ranged from 37 to 62,
with the majority (95%) of patients having repeats of less
than or equal to 50. For each additional repeat, patients
performed 5.6 fewer taps (p < 0.001; 95% CI = 8.0 to 3.3
fewer taps). Since age was included as a covariate in
the model, it takes into account that individuals with
the same CAG repeat length may be at different stages
of the disease depending on their age. The number of
taps at first visit as a function of CAG length, age, and
sex can be seen in Figure 2. The two planes are parallel,
with the female plane shifted downward by 33 taps,
which represents the effect of sex (p = 0.0001). As can
be seen, older patients and those with a larger number
of repeats perform fewer taps. In addition, it can be
seen that a male patient aged 20 years with 60 repeats
performs a similar number of taps (approximately 150)
as a male patient 75 years of age with 37 repeats. Next,
we assessed whether patients with a greater number of
CAG repeats progress at a faster rate by testing for a
time by CAG length interaction. For each additional
repeat, patients performed an additional 0.45 fewer taps
every year (p = 0.008, 95% CI = 0.78 to 0.12 fewer taps),
thus the rate of decline was faster for those with a
greater number of repeats. This relationship can be
seen in Figure 3.Figure 2 Hand tapping as a function of CAG length, age, and sex at b
of repeats perform fewer taps. In addition, females perform fewer overall ta
points on the floor are the locations of the observed data values for age an
number of repeats.Change in hand tapping as a function of TFC/stage of disease
It was also of interest to determine the relationship
between the number of taps and TFC. This was done in
two ways. First, a cross-sectional examination was made
of patients using their baseline values (i.e. the first time
they visited the clinic; Figure 4A). A linear model was
used which included age and sex as covariates, and TFC
as a continuous variable and found that for each unit
decrease in TFC, the number of taps decreased by 8.4
(95% CI = 6.8 to 10.0; p < 0.0001). On its own, TFC
accounted for 29% of the variance in the number of taps,
and age and sex accounted for an additional 8%. The sec-
ond analysis examined the relationship between tapping
and TFC within individuals (Figure 4B and C), and in this
case for each unit decrease in TFC, the number of taps
decreased by 6.3 (95% CI = 5.4 to 7.1, p < 0.0001).
Sample size estimates for a randomised trial
Based on the mean annual decrease of taps and the
patient-to-patient variability in this analysis, it is pos-
sible to estimate the number of patients required for a
randomized trial when using tapping as the primary
outcome. Figure 5 displays the results for a two group
(treated versus control) trial where the difference between
groups is tested with a two-tailed independent samples
t-test on the change in scores (number of taps at year
t minus number of taps at year 0). Since the two groups
will diverge over time if the treatment is effective, one can
either increase the sample size or follow up the patients
for a longer time to increase power. For the calculations,
power = 80%, α = 0.05, and it is assumed that no patients
are lost to follow-up or drop out. Since patients with a
greater number of CAG repeats progress at a faster
rate, the number of patients and/or follow up time can
be reduced by enriching for this population.aseline (first visit). Older patients and those with a greater number
ps than males (p = 0.0001; female plane is shifted downward). Black
d CAG length. As can be seen, there are no old patients with a high
Figure 3 Change in hand tapping over time by CAG length and sex. The rate of decline is faster in patients with a greater number of
repeats. This can be seen by the steeper slope in the time direction when CAG length = 60 compared to when CAG length = 37, and represents
the time by CAG length interaction (p = 0.008). The female plane is parallel to the male but shifted downward, indicating that females perform
fewer taps overall. Age at first visit was held constant at 35 years in this figure, and differences in the number of taps at time = 0 reflect the effect
of different CAG lengths (e.g. a male with CAG length = 60 who first visits the clinical at age 35 would perform approximately 125 taps, whereas
with CAG length = 37 he would perform approximately 250 taps). Graphs using a different age would simply shift the planes up or down.
Figure 4 Relationship between tapping and TFC. Baseline cross-sectional analysis of the number of taps by TFC (A) for the 227 patients for
which TFC data was available; horizontal lines indicate the median for each group. Population average for the association between tapping and
TFC within patients with 95% CI (B). On average, patients performed 6.3 fewer taps (triangle on the x-axis) for every unit decrease in TFC (C).
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Figure 5 Number of patients required for various effect sizes
and follow-up times. Since patients decrease (on average) at rate
of 5.1 taps per year, a therapeutic intervention that results in a 20%
improvement would have a rate of decline of 4.06 taps per year. For
a two group experiment, this effect could be detected with 80%
power after one year if 727 patients are recruited, or after four years
with 48 patients. These estimates are approximate and depend on
the proportion of individuals with long versus short CAG repeats,
the number of patients lost to follow up, and the design of
the study.
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This analysis used a simple motor hand tapping task to
follow disease progression in HD patients, at all stages
of the disease, to ascertain whether tapping changes reli-
ably over time. We found that in this patient cohort the
rate of voluntary hand tapping declined at a steady rate
(linearly) of 5.1 taps per year on average (Figure 1C) and
this rate of decline was similar between sexes. It extends
our previous study in this area by looking at larger num-
bers of patients over longer time periods, on treatment,
and thus has the advantage that it recruited all patients
attending clinic and so represents real life practice.
Several studies have now demonstrated that simple,
rather than complex, motor tasks are the most sensitive
markers of disease onset and progression in HD, and in-
clude tasks such as hand and finger tapping [9,27,28],
peg insertion task, grooved pegboard task [29], tongue
force [5], and decision making reaction time [30]. The
current study reinforces this point that a simple motor
biomarker is useful for tracking disease course and that
the impairment in voluntary movement captured in
these patients using this approach is related to functional
disability. We did not assess whether hand tapping
would be a suitable surrogate biomarker for TFC or any
other physiological endpoint such as striatal volume,
nor whether tapping has any prognostic or predictive
value. However, we have previously shown that changes
in hand tapping over time correlates with UHDRS motorscores [18] and thus the number of taps could be used as
a biomarker to assess the efficacy of compounds or other
therapeutic interventions as it is noninvasive, inexpensive,
and related to standard motor scores. In addition, tapping
has an important advantage over “wet” biomarkers as it
is not affected by sample quality, differences between
labs or clinics in terms of sample preparation and handling,
or differences between batches within a lab. It is therefore
less likely to be affected by extraneous variables that can
introduce bias and variability, making the analysis and
interpretation of results more complex [31].
Although this study has clear advantages in terms of
size and representativeness of the sample, there are a
number of limitations. These include the lack of a con-
trol group and a paucity of other clinical or imaging
measures with which to correlate our hand tapping data.
As this is a retrospective study based on patients attend-
ing the clinic for their routine appointment, we did not
include testing of controls as part of the study design.
This would be useful to include in future studies to bet-
ter understand the age dependent effects on the rate of
hand tapping. The smaller number of patients with
known CAG repeat lengths also reflects the fact that the
study is retrospective and that many patients were diag-
nosed at a time when these were not routinely recorded
as part of normal clinical practice. Finally, it should be
realised that this task can also be affected by mood and
fatigue, subject to a practice effect, and can be impaired
in patients with orthopaedic or rheumatological problems
[12]. We did not look specifically at any of these factors
but over long time scales any practice effect would likely
be negligible. In addition, the device does not rely on pres-
sure sensitive taps or large movements, and therefore joint
problems are unlikely to play a major part in determining
the hand tap score.Conclusions
We have previously reported that hand tapping is a
useful marker of motor dysfunction in HD [18] and
this new longitudinal analysis with 237 patients con-
firms this initial work and extends the findings to a lar-
ger group of manifest patients, with a wider range of
disease stages, and followed up for longer times. As
such, we provide further evidence that this test reliably
tracks disease progression and could therefore easily be
adopted in clinical trials.
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